- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05571189
Home Rehabilitation After Acute Pulmonary Embolism
The purpose of this study is to evaluate whether a home rehabilitation program after hospitalization for acute pulmonary embolism (PE) improves clinical outcomes at 3 months compared to usual care. Daily physical activity tasks that incorporate heart rate monitoring will be sent through email or text. This information could help improve the management of acute PE.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Rochester, New York, United States, 14642
- University of Rochester Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- English speaking (>18 years old). Daily messages will be sent in English.
- Acute PE with right ventricular enlargement or dysfunction defined by echocardiogram report, CT Angiogram report, or elevated cardiac biomarker (NT-pro BNP or troponin).
- Baseline testing started within 7 days of hospital discharge.
Exclusion Criteria:
- Pregnancy.
- Cardiac Effort >2.5 beats/m during 6MWT. This is for safety.
- Cardiac Effort <1.2 beats/m during 6MWT. They are unlikely to benefit.
- Resting tachycardia >120 beats/m during screening or at hospital discharge.
- Suspicion for Chronic Thromboembolic Pulmonary Hypertension.
- Systolic blood pressure >180 mmHg during screening or at hospital discharge.
- Inability to walk.
- Estimated prognosis <12 months at the time of discharge due to underlying co-morbidities.
- Advanced neurologic disease.
- Lack of access to email or text messaging.
- Inability to follow daily instructions.
- Participation in a structured exercise routine at least three days per week in the prior four weeks.
- Principal Investigator discretion
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Participants who receive daily activity message
The intervention group will receive instructions for a daily activity sent through SMS text message or email. |
Participants will receive a text each day with instructions about the daily activity they should complete for that day. |
|
Placebo Comparator: Participants who receive control message
The control group will receive daily messages to help with blinding sent through text message or email. The messages will not include activity tasks and will include phrases such as "I hope you have a good day". |
Participants will receive a text each day with no instructions about daily activity. It will have messages like "have a nice day." |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mean change in vector magnitude count as measured by actigraphy
Time Frame: 10 weeks
|
The Actigraph triaxial accelerometer will be used to monitor continuous activity at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the vector magnitude count. |
10 weeks
|
|
mean change in mean amplitude deviation as measured by actigraphy
Time Frame: 10 weeks
|
The Actigraph triaxial accelerometer will be used to monitor continuous activity at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the mean amplitude deviation. |
10 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
mean change in 6 minute walking distance
Time Frame: 12 weeks
|
12 weeks
|
|
|
mean change in heart rate during a 6 minute walk
Time Frame: 12 weeks
|
12 weeks
|
|
|
proportion or subjects who develop chronic thromboembolic pulmonary hypertension
Time Frame: 12 weeks
|
12 weeks
|
|
|
proportion of participants with post-PE syndrome
Time Frame: 12 weeks
|
Participants will be evaluated by a physician to determine if they have post PE-syndrome |
12 weeks
|
|
mean change in steps as measured by Actigraph
Time Frame: 12 weeks
|
The Actigraph triaxial accelerometer will be used to monitor the number of steps taken at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the step count. |
12 weeks
|
|
mean change in activity as measured by Actigraph
Time Frame: 12 weeks
|
The Actigraph triaxial accelerometer will be used to monitor the amount of activity taken at home on the non-dominant wrist. The accelerometer data will be downloaded and will include the amount of activity. |
12 weeks
|
|
mean change in quality of life as measured by PROMIS
Time Frame: 12 weeks
|
The PROMIS questionnaire ranges from 0-99 with higher scores indicating worse outcome. |
12 weeks
|
|
mean change in quality of life as measured by Emphasis 10
Time Frame: 12 weeks
|
The Emphasis 10 questionnaire ranges from 0-50 with higher scores indicating worse quality of life. |
12 weeks
|
|
mean change in quality of life as measured by Pulmonary Embolism quality of life questionnaire
Time Frame: 12 weeks
|
The pulmonary embolism quality of life questionnaire ranges from 1 to 27 with higher scores indicating worse outcomes. |
12 weeks
|
|
mean change in oxygen use during a 6 minute walk
Time Frame: 12 weeks
|
Oxygen use will be measured by a measured by portable K5 metabolic analyzer. |
12 weeks
|
|
mean change in carbon dioxide production during a 6 minute walk
Time Frame: 12 weeks
|
Carbon Dioxide use will be measured by a measured by portable K5 metabolic analyzer. |
12 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Daniel Lachant, DO, University of Rochester
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- STUDY00007680
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.